866-997-4948(US-Canada Toll Free)

Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 37 Pages


GlobalData, the industry analysis specialist, has released its new report, Autistic Disorder Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Autistic Disorder market. The report identifies the key trends shaping and driving the global Autistic Disorder market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Autistic Disorder sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData has estimated the global autistic disorder therapeutics market to be valued at $331m in 2009. It is expected to grow to $765m with a compound annual growth rate (CAGR) of 11.05% by 2017. This growth is primarily attributed to the high increase in prevalence and also the rapid increase in public awareness about the disease. The existing market is weak due to a lack of diagnostic techniques, and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. Autistic disorder therapeutics market primarily consists of two products, Risperidone and Abilify, and other therapeutic classes such as anti-depressants and anti-psychotics.

Scope

The report provides information on the key drivers and challenges of the Autistic Disorder market. Its scope includes: 

  • Annualized global Autistic Disorder market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as noradrenaline reuptake inhibitors, adrenergic uptake inhibitors, enzyme replacement therapy, dopamine agents, chelating agents and Gamma-amino butyric acid type B (GABA-B) receptor agonist
  • Analysis of the current and future competition in the global Autistic Disorder market. Key market players covered are Bristol-Myers Sqibb, Cellceutix Corporation, Seaside Therapeutics, Curemark LLC, Neuropharm Group and EilyLily.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Autistic Disorder therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Autistic Disorder market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Autistic Disorder market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Autistic Disorder market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Autistic Disorder Market: Introduction 5
2.1 GlobalData Pipeline Report Guidance 5

3 Autistic Disorder Market: Market Characterization 6
3.1 Autistic Disorder Therapeutics Market Size 6
3.2 Autistic Disorder Market Forecast and CAGR 7
3.3 Drivers and Barriers for the Autistic Disorder Therapeutics Market 9
3.3.1 Drivers for the Autistic Disorder Therapeutics Market 9
3.3.2 Barriers for the Autistic Disorder Therapeutics Market 9
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 11

4 Autistic Disorder Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Autistic Disorder Therapeutics Market 13
4.3.1 Risperidone 13
4.3.2 Abilify 13
4.4 Key Takeaway 15

5 Autistic Disorder Market: Pipeline Assessment 16
5.1 Overview 16
5.2 Strategic Pipeline Assessment 16
5.2.1 Technology Trends Analytic Framework 16
5.3 Autistic Disorder Therapeutics Promising Drugs under Clinical Development 17
5.4 Molecule Profile for Promising Drugs under Clinical Development 18
5.4.1 Galantamine 18
5.4.2 Atomoxetine 18
5.4.3 CM-AT 19
5.5 Autistic Disorder Market Clinical Pipeline by Mechanism of Action 20
5.6 Autistic Disorder Pipeline Pipeline by Clinical Phases of Development 21
5.6.1 Autism Disorder Therapeutics Phase III Clinical Pipeline 21
5.6.2 Autistic Disorder Therapeutics Phase II Clinical Pipeline 22
5.6.3 Autistic Disorder Therapeutics Phase I Clinical Pipeline 22
5.6.4 Autistic Disorder Therapeutics Discovery Pipeline 23
5.7 Key Takeaway 23

6 Autistic Disorder Market: Implications for Future Market Competition 24

7 Autistic Disorder Market: Future Players in the Autistic Disorder Market 25
7.1 Introduction 25
7.2 Bristol-Myers Squibb 26
7.2.1 Company Overview 26
7.2.2 Financial Performance 26
7.2.3 Business Description 26
7.3 Cellceutix Corporation 27
7.3.1 Company Overview 27
7.3.2 Financial Performance 27
7.4 Seaside Therapeutics 28
7.4.1 Company Overview 28
7.5 Curemark LLC 28
7.5.1 Company Overview 28
7.6 Eli Lilly 29
7.6.1 Company Overview 29
7.6.2 Financial Performance 29
7.6.3 Business Description 29
7.7 Neuropharm Group PLC 30
7.7.1 Overview 30
7.7.2 Major Products and Services 30
7.7.3 Autistic Disorder Disease Portfolio 31

8 Autistic Disorder Market: Appendix 32
8.1 Definitions 32
8.2 Acronyms 32
8.3 Research Methodology 32
8.3.1 Coverage 32
8.3.2 Secondary Research 33
8.3.3 Forecasting 33
8.3.4 Primary Research 36
8.3.5 Expert Panel Validation 36
8.4 Contact Us 36
8.5 Disclaimer 36
8.6 Sources 37

List of Table


Table 1: Autistic Disorder Market, Global, Revenues ($m), 2001-2009 7
Table 2: Autistic Disorder Market, Global, Revenue($m) Forecasts, 2009-2017 8
Table 3: Major Marketed Products Comparison in the Autistic Disorder therapeutics Market, 2010 14
Table 4: Autistic Disorder Therapeutics Most Promising Drugs Under Clinical Development, 17
Table 5: Autistic Disorder Therapeutics Phase III Clinical Pipeline, 2010 21
Table 6: Autistic Disorder Therapeutics Phase II Clinical Pipeline, 2010 22
Table 7: Autistic Disorder Therapeutics Phase I Clinical Pipeline, 2010 22
Table 8: Autistic Disorder Therapeutics Discovery Pipeline, 2010 23
Table 9: Cellceutix Corporation Pipeline Products, 2010 27
Table 10: Seaside Therapeutics Autism Pipeline Products, 2010 28
Table 11: Curemark LLC Autism Pipeline Products, 2010 28
Table 12: NeuroPharm Corporation Autistic Disorder Pipeline Products, 2010 31

List of Chart


Figure 1: Autistic Disorder Market, Global, Revenues ($m), 2001-2009 7
Figure 2: Autistic Disorder Market, Global, Revenue ($m) Forecasts, 2009-2017 8
Figure 3: Opportunity and Unmet Need in the Autistic Disorder Therapeutics Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Autistic Disorder Therapeutics, 2010 12
Figure 5: Technology Trends Analytic Framework of the Autistic Disorder Therapeutics Pipeline, 2010 16
Figure 6: Technology Trends Analytic Framework of the Autistic Disorder Therapeutics Pipeline Description, 2010 17
Figure 7: Autistic Disorder Market Clinical Pipeline by Mechanism of Action, 2010 20
Figure 8: Autistic Disorder Therapeutics Pipeline by Phase of Clinical Development, 2010 21
Figure 9: Implications for Future Market Competition in the Autistic Disorder Market, 2010 24
Figure 10: Autistic Disorder Therapeutics Market Clinical Pipeline by Company, 2010 25
Figure 11: GlobalData Market Forecasting Model 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *